Airain Ltd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Airain Ltd’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.8M	Sell	19,770 -10,740	-35%	-$977K	0.08%	289
2017 Q1	$2.68M	Buy	+30,510	New	+$2.71M	0.13%	191
2016 Q4	–	Sell	-24,589	Closed	-$2.27M	–	666
2016 Q3	$2.27M	Buy	+24,589	New	+$2.32M	0.13%	213
2015 Q4	–	Sell	-7,450	Closed	-$785K	–	842
2015 Q3	$785K	Buy	7,450 +1,437	+24%	+$192K	0.05%	379
2015 Q2	$822K	Buy	+6,013	New	+$745K	0.05%	399
2014 Q3	–	Sell	-62,028	Closed	-$3.86M	–	805
2014 Q2	$3.86M	Buy	+62,028	New	+$3.75M	0.32%	79
2013 Q4	–	Sell	-16,550	Closed	-$1.19M	–	575
2013 Q3	$1.19M	Buy	16,550 +10,440	+171%	+$694K	0.22%	117
2013 Q2	$341K	Buy	+6,110	New	+$381K	0.05%	346

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Airain Ltd's BMRN Position: Q2 2017 in Review

Airain Ltd reduced its BioMarin Pharmaceuticals (BMRN) stake by 35% in Q2 2017, selling an estimated $977K and leaving 19,770 shares worth $1.8M. The position accounts for 0.08% of the portfolio, ranked #289.

Airain Ltd first reported a position in BMRN in Q2 2013 and has held it in 8 quarters since. The position peaked at $3.86M in Q2 2014. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Airain Ltd held 19,770 shares of BioMarin Pharmaceuticals worth $1.8M as of Q2 2017.
Airain Ltd sold 10,740 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $977K.
BioMarin Pharmaceuticals made up 0.08% of Airain Ltd's portfolio in Q2 2017, its #289 holding.
Airain Ltd first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
Airain Ltd's BioMarin Pharmaceuticals position peaked at $3.86M in Q2 2014.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.